FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response 0.5

	s of Reporting Person	*	2. Issuer Name and Ticker or Trading Symbol <u>CORCEPT THERAPEUTICS INC</u> [CORT]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
BELANOFF	<u>IOSEPH K</u>			X	Director	10% Owner		
				x	Officer (give title	Other (specify		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	···	below)	below)		
C/O CORCEPT	THERAPEUTICS	INCORPORATED	11/10/2016		CHIEF EXECUTIVE OFFICER			
149 COMMONWEALTH DRIVE								
,			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv	idual or Joint/Group Filing (0	Check Applicable		
(Street)			······································	Line)				
MENLO PARK	СА	94025		X	Form filed by One Report	ing Person		
					Form filed by More than C Person	One Reporting		
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Transaction Disposed Of (D) (Instr. 3, 4 and 5) Code (Instr.		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(11311.4)
Common Stock	11/10/2016		М		300,000	A	\$1.5	2,464,195	D	
Common Stock	11/10/2016		S		300,000	D	\$8.9015 ⁽¹⁾	2,164,195	D	
Common Stock	11/11/2016		М		200,000	A	\$1.5	2,364,195	D	
Common Stock	11/11/2016		S		200,000	D	\$9.1015 ⁽²⁾	2,164,195	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (Right to Buy)	\$1.5	11/10/2016		М			300,000	(3)	04/16/2017	Common Stock	300,000	\$0.00	200,000	D	
Stock Option (Right to Buy)	\$1.5	11/11/2016		М			200,000	(3)	04/16/2017	Common Stock	200,000	\$0.00	0	D	

Explanation of Responses:

1. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from \$8.86 to \$9.039 per share. Detailed information on the exact number of shares sold at each sale price can be obtained upon request.

2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from \$8.91 to \$9.36 per share. Detailed information on the exact number of shares sold at each sale price can be obtained upon request.

3. Fully exercisable.

Remarks:

/s/ Charles Robb, Attorney-in-Fact for Joseph K. Belanoff

** Signature of Reporting Person

11/14/2016

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.